Loading...

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis

We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16–17...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mult Scler J Exp Transl Clin
Main Authors: Margoni, Monica, Rinaldi, Francesca, Miante, Silvia, Franciotta, Silvia, Perini, Paola, Gallo, Paolo
Format: Artigo
Sprog:Inglês
Udgivet: SAGE Publications 2019
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6747861/
https://ncbi.nlm.nih.gov/pubmed/31555463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217319875471
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!